
SIRS-Lab GmbH is a biotechnology company focused on the identification of novel biomarkers and the development of in-vitro diagnostics for the early detection of bacterial causes of infection and the inflammatory/immunological host response in intensive care medicine as well as sepsis. Three programs for the development of clinical in vitro diagnostics are presently in progress. Using state-of-the-art methods of functional genomic and proteomic research, SIRS-Lab has successfully identified several biomarker candidates. SIRS-Lab started operations in April 2001, launched its first product line in May 2002 and has currently 30 employees.
SIRS-Lab's core expertise includes expert knowledge in critical care medicine, assay design and assay development especially in the field of gene expression analysis, bio-banking, study design and CE-compliant analysis of clinical samples. As experts in the field of sepsis and rapid pathogen detection, we provide a broad variety of opportunities to corporate partner.
The companyÂ's present flagship product is Looxster, an innovative kit system for sample preparation prior to nucleic acid based detection methods of bacterial pathogens. The underlying Pureprove -Technology allows specific concentration of bacterial DNA from complex samples optimizing the ratio of pathogen DNA compared to human DNA. Thus, the sensitivity of the subsequent pathogen amplification step is significantly enhanced.
Company: | SIRS-Lab GmbH | ||
 | |||
Headquarters Address: | Winzerlaer Strasse 2 | ||
Jena 07745 | |||
Germany | |||
 | |||
Main Telephone: | +49 (0) 3641 - 508 430 | ||
 | |||
Website: | www.sirs-lab.com | ||
 | |||
Type of Organization: | Private | ||
 | |||
Industry: | Biotechnology | ||
 | |||
Key Executives: | CEO: PD Dr. Stefan Russwurm | ||
 | |||
Communications | |||
Contact: | Ulrike Knappe | ||
Phone: | +49 (0) 3641 - 508 430 | ||
Email: | knappe@sirs-lab.com | ||
 | |||
Marketing | |||
Contact: | Eva Dietzel | ||
Phone: | +49 (0) 3641 - 508 430 | ||
Email: | dietzel@sirs-lab.de |